Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) EBT (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed EBT for 11 consecutive years, with -$616323.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 81.94% year-over-year to -$616323.0, compared with a TTM value of -$7.1 million through Sep 2025, down 243.76%, and an annual FY2024 reading of $5.7 million, up 145.56% over the prior year.
  • EBT was -$616323.0 for Q3 2025 at Kiora Pharmaceuticals, up from -$2.3 million in the prior quarter.
  • Across five years, EBT topped out at $13.5 million in Q1 2024 and bottomed at -$14.4 million in Q4 2021.
  • Average EBT over 5 years is -$2.0 million, with a median of -$2.2 million recorded in 2024.
  • The sharpest move saw EBT plummeted 5345.16% in 2022, then surged 801.91% in 2024.
  • Year by year, EBT stood at -$14.4 million in 2021, then surged by 74.27% to -$3.7 million in 2022, then grew by 22.42% to -$2.9 million in 2023, then rose by 24.87% to -$2.2 million in 2024, then skyrocketed by 71.45% to -$616323.0 in 2025.
  • Business Quant data shows EBT for KPRX at -$616323.0 in Q3 2025, -$2.3 million in Q2 2025, and -$2.1 million in Q1 2025.